News ArticleIKS Health Doubles Revenue with 103.9% YoY Growth and Boosts EBITDA by 62.5% in Q2 FY27 Post TruBridge Deal
Company reports INR 15,925 million revenue and PAT of INR 2,177 million, alongside new strategic healthcare client partnerships
IKS Health announced its Q2 FY27 financial results highlighting 103.9% year-on-year revenue growth to INR 15,925 million and a 62.5% increase in EBITDA aided by the acquisition of TruBridge. The company also secured new major client partnerships and reported a PAT rise of 20.4% year-on-year.
Inventurus Knowledge Solutions Limited
General / Other
Inventurus Knowledge Solutions Limited (IKS Health) announced strong Q2 FY27 financial results with revenue surpassing INR 15,900 million, marking a 103.9% year-on-year increase supported by its TruBridge acquisition and sustained organic growth.
The company’s EBITDA rose to INR 4,415 million during Q2 FY27, a 62.5% increase year-on-year, with EBITDA margins at 27.7%. Net profit after tax (PAT) grew by 20.4% to INR 2,177 million, reflecting operational scale expansion and improved earnings power.
IKS Health consolidated TruBridge within 82 days since acquisition, with PAT and EPS accretive contributions starting immediately in Q2 FY27, demonstrating integration success and fast financial benefits.
The company secured several key client engagements, including partnerships with White-Wilson Medical Center, Evolve Orthopedic Partners, Augusta Health, UMass Memorial Health, and MISH Hospital & Clinics to provide comprehensive revenue cycle management (RCM), data migration, scheduling, and electronic health record (EHR) integration services.
Management emphasized continued operational synergies, a focus on sustainable shareholder value, and advancement towards an AI-native healthcare operating system improving clinical and financial outcomes.
Highlights
- Q2 FY27 total revenue reached INR 15,925 million, up 103.9% year-on-year and 78.2% quarter-on-quarter.
- EBITDA increased by 62.5% year-on-year to INR 4,415 million with a margin of 27.7%.
- Net profit after tax (PAT) grew 20.4% year-on-year to INR 2,177 million.
- TruBridge acquisition was consolidated within Q2 FY27 (82 days) and was PAT/EPS accretive from the first quarter post-acquisition.
- New contracts with major US healthcare providers including White-Wilson Medical Center and UMass Memorial Health.
- Focused on scaling AI-driven care enablement platform and strengthening operational synergies going forward.
Key Data Snapshot
What happened
- IKS Health reported strong financial results for Q2 FY27 ending September 30, 2026.
- Revenue grew 103.9% year-on-year to INR 15,925 million and 78.2% quarter-on-quarter.
- EBITDA increased by 62.5% year-on-year with INR 4,415 million earned.
- Net profit after tax rose by 20.4% year-on-year to INR 2,177 million.
- The TruBridge acquisition was consolidated within Q2 FY27, contributing positively to profit and earnings per share from the first quarter post-acquisition.
Key details
- IKS Health’s EBITDA margin in Q2 FY27 was 27.7% and PAT margin was 13.7%.
- TruBridge integration completed in 82 days, showing rapid consolidation impact.
- New client partnerships secured with US healthcare entities, including end-to-end revenue cycle management and EHR platform integration.
- The company focuses on building an AI-native healthcare operating system to transform operations, revenues, and quality of care.
Transaction details
- TruBridge acquisition contributes to immediate profit and EPS accretion starting Q2 FY27.
- Integration advances the company’s care enablement platform capabilities and operational scale.
- The consolidation of TruBridge reflects financial accretion and expands IKS Health’s service offerings.
Strategic context
- IKS Health aims to create smarter healthcare operations via AI, agentic workflows, and human expertise.
- The company serves large health systems and specialty practices across the US through its Care Enablement platform.
- The acquisition and client wins emphasize a focus on sustainable long-term shareholder value and operating discipline.
Risks and conditions
- Forward-looking statements in the release are subject to risks and uncertainties that may cause actual results to differ materially.
- IKS Health disclaims any obligation to update these statements in the future.
Highlights
- Q2 FY27 total revenue reached INR 15,925 million, up 103.9% year-on-year and 78.2% quarter-on-quarter.
- EBITDA increased by 62.5% year-on-year to INR 4,415 million with a margin of 27.7%.
- Net profit after tax (PAT) grew 20.4% year-on-year to INR 2,177 million.
- TruBridge acquisition was consolidated within Q2 FY27 (82 days) and was PAT/EPS accretive from the first quarter post-acquisition.
- New contracts with major US healthcare providers including White-Wilson Medical Center and UMass Memorial Health.
- Focused on scaling AI-driven care enablement platform and strengthening operational synergies going forward.
Disclosures
- Listing compliance with BSE and NSE regulations
Source Information
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sansera Engineering Achieves Record INR 10,915 Million Quarterly Revenue and 59% Normalised PAT Growth in Q2 FY27
Sansera Engineering Limited reported its highest-ever quarterly revenue of INR 10,915 million for Q2 FY27, a 32% increase year-over-year, alongside a normalized profit after tax of INR 1,000 million, up 59% YoY excluding an exceptional litigation-related cost.
Read Full Story
Godfrey Phillips India Declares ₹10 Interim Dividend and Posts ₹16,298 Lakh Profit for Q2 FY2027
Godfrey Phillips India Limited declared an interim dividend of 500% or ₹10 per equity share for the financial year ending March 31, 2027, while reporting an unaudited standalone net profit of ₹16,298 lakh for the quarter ended September 30, 2026.
Read Full Story
Sai Life Sciences Reports 23% Revenue Growth in Q2 FY27 with ₹621 Crore Capex Investment
Sai Life Sciences Limited posted a 23% year-on-year revenue increase to ₹659 crore for Q2 FY27, with sustained EBITDA margin of 28% and a capital expenditure of ₹621 crore invested during the first half of the fiscal year, as the company strengthens its global pharmaceutical partnerships and expands capacity.
Read Full Story
